Danica Pension Livsforsikringsaktieselskab Purchases 56,400 Shares of Merck & Co., Inc. $MRK

Danica Pension Livsforsikringsaktieselskab raised its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 41.6% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 191,871 shares of the company's stock after acquiring an additional 56,400 shares during the period. Danica Pension Livsforsikringsaktieselskab's holdings in Merck & Co., Inc. were worth $20,196,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in MRK. DLD Asset Management LP raised its stake in shares of Merck & Co., Inc. by 30.1% during the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $585,192,000. Invesco Ltd. raised its stake in shares of Merck & Co., Inc. by 16.6% during the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock worth $1,665,585,000 after purchasing an additional 2,821,766 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Merck & Co., Inc. by 20.7% during the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock worth $1,336,877,000 after purchasing an additional 2,735,459 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Merck & Co., Inc. by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock worth $26,770,014,000 after purchasing an additional 2,185,853 shares in the last quarter. Institutional investors own 76.07% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on MRK shares. JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an "overweight" rating in a research note on Monday, April 6th. Wall Street Zen upgraded Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research note on Saturday, March 28th. Guggenheim upped their price objective on Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a "buy" rating in a research note on Friday, February 6th. Citigroup upped their price objective on Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a "neutral" rating in a research note on Friday, March 20th. Finally, Barclays started coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They set an "overweight" rating and a $140.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, Merck & Co., Inc. has an average rating of "Moderate Buy" and an average price target of $128.47.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 20,000 shares of the company's stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the transaction, the chief marketing officer directly owned 80,615 shares of the company's stock, valued at $9,825,356.20. This represents a 19.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Richard R. Deluca sold 37,685 shares of the company's stock in a transaction on Friday, February 6th. The shares were sold at an average price of $120.92, for a total value of $4,556,870.20. Following the completion of the transaction, the executive vice president directly owned 160,174 shares in the company, valued at approximately $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 320,176 shares of company stock worth $38,281,735. 0.17% of the stock is currently owned by company insiders.

Merck & Co., Inc. Stock Performance

Shares of NYSE MRK opened at $109.33 on Friday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The stock's fifty day moving average price is $117.69 and its two-hundred day moving average price is $107.39. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The firm has a market cap of $270.03 billion, a price-to-earnings ratio of 15.02, a P/E/G ratio of 2.25 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the firm posted $2.22 EPS. The company's revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 4.89 EPS for the current year.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results and product momentum: Merck beat Q1 revenue and adjusted EPS expectations, driven by continued Keytruda demand and contributions from newer launches (Winrevair reported at ~$525M), which underpin near‑term revenue growth. Merck Sales Beat As Winrevair Hits $525 Million
• Positive Sentiment: Management raised adjusted EPS guidance and emphasized oncology strength: Merck narrowed its 2026 guidance range but lifted its profit outlook on stronger Keytruda and new product trends, a positive for earnings power even as revenue bands were tightened. Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
• Positive Sentiment: Clinical pipeline progress: Merck dosed the first patient in Phase 3 studies of enpatoran for lupus skin manifestations — a near‑term clinical milestone that could add long‑term pipeline value if successful. Merck Announces First Dose in Phase 3 Study with Enpatoran
• Neutral Sentiment: Calls and disclosures available: The full Q1 earnings call transcript and the investor slide deck are posted for deeper review of sales mix, margin drivers and forward guidance assumptions. Q1 2026 Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: Minor analyst estimate moves: Some shops trimmed FY forecasts modestly (e.g., Erste’s slight EPS tweak), indicating traders are tweaking models but not overhauling consensus. MRK Q1 Earnings & Sales Beat; 2026 Sales View Tightened
• Negative Sentiment: One‑time acquisition charge produced a GAAP loss: Merck reported a quarterly loss driven by a Cidara‑related acquisition charge, which suppresses headline earnings and can weigh on near‑term sentiment. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Tighter revenue guidance and mixed product trends: Management narrowed the sales range for 2026 and flagged mixed growth among some newer and legacy products, which leaves upside constrained and raises uncertainty about sustained top‑line acceleration. Merck Q1 earnings beat; 2026 guidance narrowed
• Negative Sentiment: Market concerns about future sales erosion: Commentary and coverage highlighted risks from expected declines in certain legacy drugs (HPV vaccine, diabetes medicine) and the company’s efforts to offset those losses, which contributes to investor caution. Merck Stock Falls After Earnings

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.